Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11
Published: Sept. 11, 2024
The effectiveness and safety of a novel class hypoglycemic medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors have not been completely established in relation to acute heart failure (AHF). Consequently, we sought compare the prognostic outcomes patients administered SGLT2 for treatment AHF.
Language: Английский
JAMA, Journal Year: 2024, Volume and Issue: 332(5), P. 401 - 401
Published: June 14, 2024
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in patients with type diabetes, heart failure, and chronic kidney disease, but their effect on of critically ill organ failure is unknown.
Language: Английский
Citations
14
European Journal of Internal Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
1
ESC Heart Failure, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 31, 2025
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed evaluate the impact on worsening renal function (WRF) by adding DAPA as compared standard decongestive therapy loop diuretics alone. Methods and results enrolled 114 consecutive acute decompensated failure (ADHF) left ventricular ejection fraction (LVEF) of less than 50%. The were prospectively randomized be assigned either group who received at dose 10 mg once daily within 24 h after admission or conventional (CON group) All adjusted increasing decreasing diuretic maintain 1–2 mL/kg/h urine output. primary endpoint was incidence WRF, which defined an increase in serum creatinine ≥0.3 mg/dL from baseline. median age 77 [interquartile range (IQR): 64, 85] years, 35% female LVEF 33 [IQR: 28, 38] %. There no significant difference WRF between two groups (16.1%, n = 9 vs. 12.1%, 7, P value 0.54). total through day 7 lower CON (184 ± 79.5 214 66.5 mg, 0.03). Conclusions This prospective trial revealed addition reduced without WRF.
Language: Английский
Citations
1
Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(13), P. 1241 - 1267
Published: Aug. 8, 2024
Language: Английский
Citations
6
Cardiorenal Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21
Published: Jan. 8, 2025
Introduction: Antigen carbohydrate 125 (CA125) has emerged as a proxy of fluid overload and inflammation in acute heart failure (AHF). We aimed to evaluate the influence dapagliflozin on CA125 levels within first weeks after discharge whether changes were related 6-month adverse clinical outcomes. Methods: In this retrospective observational study, data from 956 AHF patients discharged tertiary hospital analyzed. assessed during index admission (visit 1) at median 26 (15-39) days 2). The primary endpoint was its correlation with risk death recurrent readmissions (any or AHF-related). Multivariable mixed regression two-equation count model used for analyses. Results: mean age cohort 73.1±11.1 years, 54.8% males, 43.5% showed left ventricular ejection fraction ≥50%, 18.7% received discharge. Dapagliflozin treatment associated greater reduction follow-up (-24 U/mL) compared non-dapagliflozin (-14 U/mL, p=0.034). magnitude (per decrease 10 U/ml) significantly lower (IRR=0.98, 95% CI=0.96-0.99; p=0.049), all-cause (IRR=0.99, CI=0.98-0.99; p=0.003), HF-readmissions CI=0.97-0.99; p<0.001). Conclusion: following an episode identified
Language: Английский
Citations
0
Journal of the Endocrine Society, Journal Year: 2025, Volume and Issue: 9(2)
Published: Jan. 6, 2025
Abstract Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally approved by the US Food and Drug Administration for glycemic control in type diabetes mellitus (DM2), have shown substantial cardiovascular renal benefits, leading to their expanded use managing heart failure (HF) chronic kidney disease outpatient setting. Despite these inpatient hyperglycemia management is not universally endorsed due safety concerns inadequate data. However, emerging evidence suggests potential advantages of initiating SGLT2i treatment patients during hospitalization setting HF. While SGLT2is are recommended hyperglycemia, initiation HF provides significant benefits. We review current literature on pros cons using hospitalized DM2 provide guidance careful patient selection risk mitigation use.
Language: Английский
Citations
0
Glomerular Diseases, Journal Year: 2025, Volume and Issue: 5(1), P. 119 - 132
Published: Jan. 23, 2025
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have significantly impacted the management of diabetic kidney disease (DKD) and heart failure (HF), providing benefits beyond glycemic control. This review examines mechanisms through which SGLT2is provide renal cardiovascular protection assesses their clinical efficacy. Summary: By inducing glucosuria natriuresis, alleviate multiple complications induced by chronic hyperglycemia. Moreover, reduce albuminuria, improve tubular function, modulate erythropoiesis. Additionally, they mitigate inflammation fibrosis decreasing oxidative stress downregulating proinflammatory pathways. Clinical trials demonstrated significant reductions in events among patients with type diabetes mellitus. A comprehensive literature was conducted PubMed, highlighting effects results major involving SGLT2is. Key Messages: play a crucial role DKD HF addressing pathogenic Currently, are included guidelines for management, extend to nondiabetic populations. Further research is needed explore SGLT2is’ multifaceted potential applications across diverse patient populations different etiologies.
Language: Английский
Citations
0
Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 7, 2025
Introduction Major global guidelines currently recommend sodium-glucose co-transporter-2 inhibitors (SGLT-2i) as the first-line agents in people with type 2 diabetes (T2D) who have either established cardiovascular disease (eCVD), heart failure (HF), or chronic kidney (CKD), regardless of baseline glycated hemoglobin. Moreover, SGLT-2i are included guideline-directed medical therapy one pillars for HF and CKD, T2D. These recommendations based on positive cardio-renal outcomes from several randomized controlled trials (RCTs).
Language: Английский
Citations
0
European Journal of Heart Failure, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 20, 2025
Language: Английский
Citations
0
Diagnostics, Journal Year: 2025, Volume and Issue: 15(5), P. 540 - 540
Published: Feb. 23, 2025
Acute heart failure (AHF) is a complex clinical syndrome characterized by the rapid or gradual onset of symptoms and/or signs (HF), leading to an unplanned hospital admission emergency department visit. AHF cause hospitalization in patients over 65 years, thus significantly impacting public health care. However, its prognosis remains poor with high rates mortality and rehospitalization. Many pre-existing cardiac conditions can lead AHF, but it also arise de novo due acute events. Therefore, understanding etiology could improve patient management outcomes. Cardiomyopathies (CMPs) are heterogeneous group muscle diseases, including dilated cardiomyopathy (DCM), hypertrophic (HCM), restrictive (RCM), non-dilated (NDLVC), arrhythmogenic right ventricular (ARVC), that frequently present HF. Patients CMPs under-represented studies compared other etiologies, therefore therapeutic responses prognoses remain unknown. In DCM, represents most frequent death despite treatment improvements. Additionally, DCM first indication for transplant (HT) among young middle-aged adults. HCM, progression rare more concomitant severe left ventricle (LV) obstruction hypertrophy LV systolic dysfunction. HF natural evolution RCM associated outcomes irrespective etiology. Furthermore, while occurrence ARVC, this condition NDLVC currently manuscript, we assessed available evidence on CMPs. Data presentation, management, according specific limited. Future assessing treatment, warranted.
Language: Английский
Citations
0